Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panax notoginseng flower tea is an herbal therapeutic preparation derived from the inflorescence of *Panax notoginseng* (Burk.) F.H. Chen, a plant indigenous to the Yunnan province of China. Specifically developed and clinically evaluated by the Yunnan Provincial Psychiatric Hospital, the tea is utilized for its antidepressant and sedative properties. Its primary active constituents are dammarane-type triterpene saponins, most notably ginsenoside Rb3, ginsenoside Rb1, ginsenoside Rc, and various notoginsenosides. These compounds are believed to exert antidepressant effects by modulating the hypothalamic-pituitary-adrenal (HPA) axis, thereby normalizing cortisol levels, and by enhancing monoaminergic neurotransmission through the inhibition of serotonin and norepinephrine reuptake. Additionally, the tea has been shown to upregulate brain-derived neurotrophic factor (BDNF) and provide neuroprotective benefits against neuroinflammation. It is traditionally used in Chinese medicine to clear heat and calm the liver, and it is currently explored as a natural alternative or adjunct for patients with mild to moderate depression and insomnia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on panax notoginseng flower tea.